Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720001 · ClinicalTrials.gov registry record
Florbetaben PET Imaging in PPA
A clinical trial of Alzheimer Disease and Primary Progressive Aphasia, sponsored by University of Chicago.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT04720001: Completed study of Alzheimer Disease and Primary Progressive Aphasia, sponsored by University of Chicago.
NCT04720001 is a study of Alzheimer Disease and Primary Progressive Aphasia that has completed, run by University of Chicago. The registered enrollment target is 1 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04720001, a study of Alzheimer Disease and Primary Progressive Aphasia, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
Primary Outcome
Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.
Conditions Studied
Interventions
- DEVICE PET
- DRUG Florbetaben F18
Study Locations (1)
Illinois
- University of Chicago - American School Building - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2021-02-26 |
What the finished NCT04720001 record still lists
NCT04720001 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which PET is the first listed.
NCT04720001 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04720001 about?
NCT04720001 is a clinical study titled "Florbetaben PET Imaging in PPA". The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
What is the current status of trial NCT04720001?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2018-08-23. Estimated completion is 2021-02-26.
What conditions does trial NCT04720001 study?
This clinical trial studies the following conditions: Alzheimer Disease, Primary Progressive Aphasia.
What interventions are being tested in trial NCT04720001?
The interventions under investigation include: PET (DEVICE), Florbetaben F18 (DRUG).
Who is sponsoring clinical trial NCT04720001?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04720001 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04720001's enrollment target sits among peer trials
1 307th of 306 the lowest of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI